

ABSTRACT

A method of treating gastrointestinal cancers dependent on the prohormones amidated gastrin-17 and glycine extended G-17, comprising the administration to the patient of an anti-gastrin 17 immunogen which induces antibodies which bind and neutralize amidated and glycine-extended gastrin-17.